Welcome to our dedicated page for SRNEQ news (Ticker: SRNEQ), a resource for investors and traders seeking the latest updates and insights on SRNEQ stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SRNEQ's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SRNEQ's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sorrento Therapeutics, Inc. (OTC: SRNEQ) announced on April 25, 2023, that the U.S. Bankruptcy Court for the Southern District of Texas extended the restrictions on the transfer of shares for Scilex Holding Company, distributed as a dividend on January 19, 2023. This extension defers the selling, transferring, or disposing of these distributed shares from May 11, 2023, to September 1, 2023. The restrictions apply solely to the Distributed Stock and do not affect other Scilex securities held by Sorrento. Sorrento is focused on developing therapies for cancer, pain, and infectious diseases and has ongoing clinical trials for several novel products.